Alnylam posts strong Onpattro sales as competition heats up

Sales of Alnylam Pharmaceuticals' rare disease drug Onpattro more than doubled between the fourth quarter of last year and the first three months of 2019, outstripping expectations and helping to ease worries of a slow start for the therapy.